CIK 0001850119
- Emerging growth company
Century Therapeutics, Inc.
Sign in to watch- Ticker
- IPSC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 842040295
- Phone
- +1 215-981-4000
- Business address
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,212
- in 5 filings
Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-09 | Casdin Eli Director | Grant or award · Stock Option (right to buy) | +19,872 | 19,872 | ||
| 2022-06-09 | JIMENEZ JOSEPH Director | Grant or award · Stock Option (right to buy) | +19,872 | 19,872 | ||
| 2022-06-09 | Carlo Rizzuto Director | Grant or award · Stock Option (right to buy) | +19,872 | 19,872 | ||
| 2022-01-31 | Versant Venture Capital VI, L.P. 10% owner | Other disposition | −178,996 | 12,366,814 | ||
| 2022-01-25 | Diem Michael Craig Chief Business Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2022-01-25 | Farid Adrienne Chief Operations Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2022-01-25 | Borges Luis Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2022-01-25 | Levitsky Hyam President of R&D | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2022-01-25 | Russotti Gregory Chief Technology Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2022-01-25 | Flores Osvaldo Chief Executive Officer | Grant or award · Stock Option (right to buy) | +315,000 | 315,000 | ||
| 2022-01-25 | Carr Douglas VP of Finance and Operations | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-12-23 | Versant Venture Capital VI, L.P. 10% owner | Other disposition | −371,004 | 12,545,810 | ||
| 2021-06-22 | FUJIFILM Cellular Dynamics, Inc. 10% owner | Conversion | +3,974,404 | 6,955,207 | ||
| 2021-06-22 | FUJIFILM Cellular Dynamics, Inc. 10% owner | Conversion · Series A Convertible Preferred Stock | −10,000,000 | 0 | ||
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT 10% owner | Conversion | +10,390,600 | 10,390,600 | ||
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT 10% owner | Conversion | +1,535,238 | 11,925,838 | ||
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT 10% owner | Purchase | +750,000 | $20.00 | $15.0M | 12,675,838 |
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT 10% owner | Conversion · Series B Preferred Stock | −26,143,790 | 0 | ||
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT 10% owner | Conversion · Series C Preferred Stock | −3,862,813 | 0 | ||
| 2021-06-22 | Versant Venture Capital VI, L.P. 10% owner | Conversion | +9,936,011 | 12,916,814 |
Page 11 of 12 · 233 trades